Aprepitant + IfosfamideModerate
Intervention Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions.
Source: FDA drug label - aprepitant
Aprepitant Interactions
Brand names: Aponvie
11 interactions on record
Aprepitant + AlprazolamUnknown
Benzodiazepines Clinical Impact Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ] .
Source: FDA drug label - aprepitant
Aprepitant + ClarithromycinUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant
Aprepitant + ItraconazoleUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant
Aprepitant + KetoconazoleUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant
Methylprednisolone Clinical Impact Increased methylprednisolone exposure [see Clinical Pharmacology (12.3) ] . Intervention Reduce the dose of oral methylprednisolone by approximately 50% on Days 1 and 2 for patients receiving HEC and on Day 1 for patients receiving MEC. Reduce the dose of intravenous methylprednisolone by 25% on Days 1 and 2 for patients receiving HEC and on Day 1 for patients receiving MEC.
Source: FDA drug label - aprepitant
Aprepitant + MidazolamUnknown
Benzodiazepines Clinical Impact Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ] .
Source: FDA drug label - aprepitant
Aprepitant + NelfinavirUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant
Aprepitant + RitonavirUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant
Aprepitant + TriazolamUnknown
Benzodiazepines Clinical Impact Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ] .
Source: FDA drug label - aprepitant
Aprepitant + TroleandomycinUnknown
Examples ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir Strong CYP3A4 Inducers Clinical Impact Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of APONVIE [see Clinical Pharmacology (12.3) ].
Source: FDA drug label - aprepitant